Acute graft-versus-host disease in patients with Fanconi anemia or acquired aplastic anemia undergoing bone marrow transplantation from HLA-identical sibling donors: Risk factors and influence on outcome

Blood

Volumn 103, Issue 1, 2004, Pages 73-77

  Guardiola, Philippe ^b   Socié, Gérard ^b   Li, Xiaxin ^b   Ribaud, Patricia ^b   Devergie, Agnès ^b   Espérou, Hélène ^b   Richard, Patrice ^b   Traineau, Richard ^b   Janin, Anne ^b   Gluckman, Eliane ^a  

^a SAINT LOUIS HOSPITAL   (France)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; METHOTREXATE; METHYLPREDNISOLONE; THYMOCYTE ANTIBODY;

ADOLESCENT; ADULT; APLASTIC ANEMIA; ARTICLE; BONE MARROW TRANSPLANTATION; CHILD; CORTICOSTEROID THERAPY; DRUG RESPONSE; FANCONI ANEMIA; FEMALE; GRAFT VERSUS HOST REACTION; HEAD AND NECK CARCINOMA; HISTOCOMPATIBILITY; HLA SYSTEM; HORMONE RESISTANCE; HUMAN; INCIDENCE; LETHALITY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK FACTOR; SECOND CANCER; SIBLING; SURVIVAL; TREATMENT OUTCOME; X IRRADIATION;

EID: 9144236362     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2003-06-2146     Document Type: Article

References (35)

1. D'Andrea AD, Grompe M. Molecular biology of Fanconi anemia: implications for diagnosis and therapy. Blood. 1997;90:1725-1736.
2. Young NS, Alter BP. Clinical features of Fanconi's anemia, In: Young NS, Alter BP, eds. Aplastic Anemia Acquired and Inherited. Philadelphia, PA: Saunders; 1994:275-309.
3. Butturini A, Gale RP, Verlander PC, Adler-Brecher B, Gillio AP, Auerbach AD. Hematologic abnormalities in Fanconi anemia: an International Fanconi Anemia Registry study. Blood. 1994;84:1650-1655.
4. Gluckman E, Auerbach AD, Horowitz MH, et al. Bone marrow transplantation for Fanconi anemia. Blood. 1995;86:2856-2862.
5. Berger R, Bernheim A, Gluckman E, Gisselbrecht C. In vitro effect of cyclophosphamide metabolites on chromosomes of Fanconi anaemia patients. Br J Haematol. 1980;45:565-568.
6. Gluckman E, Devergie A, Dutreix J. Radiosensitivity in Fanconi anaemia: application to the conditioning regimen for bone marrow transplantation. Br J Haematol. 1983;54:431-440.
7. Gluckman E, Devergie A, Schaison G, et al. Bone marrow transplantation in Fanconi anaemia. Br J Haematol. 1980;45:557-564.
8. Socié G, Gluckman E, Raynal B, et al. Bone marrow transplantation for Fanconi anemia using low-dose cyclophosphamide/thoracoabdominal irradiation as conditioning regimen: chimerism study by the polymerase chain reaction. Blood. 1993;82:2249-2256.
9. D'Andrea AD, Grompe M. The Fanconi anaemia/BRCA pathway. Nat Rev Cancer. 2003;3:23-34.
10. Ferrara JLM, Deeg HJ, Burakoff SL. Graft-vs-Host Disease. 2nd ed, rev and exp. New York, NY: Marcel Dekker, Inc; 1997.
11. Auerbach AD, Wolman SR. Susceptibility of Fanconi's anaemia fibroblasts to chromosome damage by carcinogens. Nature. 1976;261:494-496.
12. Young NS. Introduction: acquired aplastic anemia. Semin Hematol. 2000;37:2.
13. Gluckman E, Socié G, Devergie A, et al. Bone marrow transplantation in 107 patients with severe aplastic anemia using cyclophosphamide and thoraco-abdominal irradiation for conditioning: long-term follow-up. Blood. 1991;78:2451-2455.
14. Storb R, Deeg HJ, Whitehead J, et al. Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia. N Engl J Med. 1986;314:729-735.
15. McCloy M, Almeida A, Daly P, et al. Fludarabine-based stem cell transplantation protocol for Fanconi's anaemia in myelodysplastic transformation. Br J Haematol. 2001;112:427-429.
16. Thomas E, Storb R, Clift RA, et al. Bone marrow transplantation. N Engl J Med. 1975;292:832-843.
17. Glucksberg H, Storb R, Fefer A, et al. Clinical manifestations of graft-versus-host disease in human recipient of marrow from HLA-matched sibling donors. Transplantation. 1974;18:295-304.
18. Shulman HM, Sullivan KM, Weiden PL, et al. Chronic graft-versus-host syndrome in man: a long-term clinicopathologic study of 20 Seattle patients. Am J Med. 1980;69:204-217.
19. Gray RJ. Spline-based tests in survival analysis. Biometrics. 1994;50:640-652.
20. Kaplan EL, Meier P. Non parametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457-481.
21. Cox DR. Regression models and life tables. J R Stat Soc. 1972;34:187-220.
22. Harrel FE Jr, Lee KL, Mark DB. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med. 1996;15:361-387.
23. MacMillan ML, Auerbach AD, Davies SM, et al. Haematopoietic cell transplantation in patients with Fanconi anaemia using alternate donors: results of a total body irradiation dose escalation trial. Br J Haematol. 2000;109:121-129.
24. Guardiola P, Pasquini R, Dokal I, et al. Outcome of 69 allogeneic stem cell transplantations for Fanconi anemia using HLA-matched unrelated donors: a study on behalf of the European Group for Blood and Marrow Transplantation. Blood. 2000;95:422-429.
25. Dufour C, Rondelli R, Locatelli F, et al. Stem cell transplantation from HLA-matched related donor for Fanconi's anaemia: a retrospective review of the multicentric Italian experience on behalf of AIEOP-GITMO. Br J Haematol. 2001;112:796-805.
26. Locatelli F, Bruno B, Zecca M, et al. Cyclosporin A and short-term methotrexate versus cyclosporin A as graft versus host disease prophylaxis in patients with severe aplastic anemia given allogeneic bone marrow transplantation from an HLA-identical sibling: results of a GITMO/EBMT randomized trial. Blood. 2000;96:1690-1697.
27. Kohli-Kumar M, Morris C, DeLaat C, et al. Bone marrow transplantation in Fanconi anemia using matched sibling donors. Blood. 1994;84:2050-2054.
28. Yu C, Seidel K, Nash RA, Deeg HJ, et al. Synergism between mycophenolate mofetit and cyclosporine in preventing graft-versus-host disease among lethally irradiated dogs given DLA-non-identical unrelated marrow grafts. Blood. 1998;91:2581-2587.
29. McSweeney PA, Niederwieser D, Shizuru JA, et al. Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects. Blood. 2001;97:3390-3400.
30. Medeiros C, Zanis-Neto J, Pasquini R. Bone marrow transplantation for patients with Fanconi anemia: reduced doses of cyclophosphamide without irradiation as conditioning. Bone Marrow Transplant. 1999;24:849-852.
31. de Medeiros CR, Silva LM, Pasquini R. Unrelated cord blood transplantation in a Fanconi anemia patient using fludarabine-based conditioning. Bone Marrow Transplant. 2001;28:110-112.
32. Chan KW, Li CK, Worth LL, et al. A fludarabine-based conditioning regimen for severe aplastic anemia. Bone Marrow Transplant. 2001;27:125-128.
33. Boulad F, Gillio A, Small TN, et al. Stem cell transplantation for the treatment of Fanconi anaemia using a fludarabine-based cytoreductive regimen and T-cell-depleted related HLA-mis-matched peripheral blood stem cell grafts. Br J Haematol. 2000;111:1153-1157.
34. Kapelushnik J, Or R, Slavin S, Nagler A. A fludarabine-based protocol for bone marrow transplantation in Fanconi's anemia. Bone Marrow Transplant. 1997;20:1109-1110.
35. Rosenberg PS, Greene MH, Alter BP. Cancer incidence in persons with Fanconi anemia. Blood. 2003;101:822-826.